StockData
BioLineRx Ltd. logo

BioLineRx Ltd. (BLRX) stock

BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 3/30
$1.12−0.03 (-2.61%)

Close on Nov 17, 2026Market cap $4.87MP/E –Yield –

BioLineRx gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2025 it was 80.5%, against 68.0% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202580.5%+12.5
FY2024Dec 31, 202468.0%+44.9
FY2023Dec 31, 202323.1%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202679.9%–
Q2 FY2025Jun 30, 202576.3%–
Q2 FY2024Jun 30, 202483.4%–

More BioLineRx figures

See a number that looks wrong?